Search results
Emcure Pharmaceuticals IPO last bidding date today. Should you subscribe? Check GMP, subscription...
Livemint· 2 days agoEmcure Pharmaceuticals IPO aims to utilise funds to reduce long-term debt and focus on important...
Bhajan Samraat Anup Jalota attends birthday celebration of Anuja Sahai and launches the...
Mid Day· 2 days agoKalyug Ka Krishnansh is a unique and contemporary take on traditional themes, blending the essence...
Emcure Pharmaceuticals IPO opens today: GMP, subscription status, review, other details. Apply or...
Livemint· 4 days agoEmcure Pharmaceuticals IPO subscription opens with ₹582 crore raised from anchor investors. Price...
Shark Tank Judge Namita Thapar To Earn Rs 127 Crore From Emcure IPO
NDTV· 4 days agoNamita Thapar, the Executive Director of Emcure Pharmaceuticals, is set to earn approximately Rs...
Emcure Pharmaceuticals IPO: Issue booked 4.98 times on the second bidding day. Check latest GMP,...
Livemint· 3 days agoEmcure Pharmaceuticals IPO subscription status: Emcure Pharmaceuticals, backed by Bain Capital,...
Mira-Bhayandar: MBVV Police Organises 'Prabodh' Inter-College Contest On International Day Against...
Free Press Journal· 12 hours agoApart from principals and teachers, around 900 students from 11 colleges falling under the...
Emcure Pharmaceuticals' IPO subscription closes today | India Infoline
India Infoline· 1 day agoOn the third day of bidding, at the time of writing on July 5, 2024 at 12:12 pm, Emcure Pharmaceuticals IPO is witnessing a overall subscription of 8.83 times.
Emcure Pharma IPO to open on July 3, Shark Namita Thapar likely to earn ₹127 crore - CNBC TV18
CNBC TV18· 5 days agoThe initial share sale of Pune-based Emcure Pharmaceuticals will open for public subscription on...
Emcure Pharmaceuticals IPO Day 2: From key risks to financials, here are 10 things to know from RHP...
Livemint· 3 days agoEmcure Pharmaceuticals IPO saw positive investor response with overwhelming demand, offering new...
Shark Tank's Namita Thapar to make 293x on her Emcure Pharma exit
CNBC Awaaz· 6 days agoAt the upper end of the price band, Thapar will achieve a 293-fold return. The price band for Emcure...